GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Conjugated meningococcal ACWY-TT (vaccine)Biological: DTPa/Hib containing vaccineBiological: MeningitecBiological: Mencevax ACWY
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 508
- Registration Number
- NCT00126984
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
- Conditions
- MeaslesMumpsRubellaVaricella
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00127010
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
- Conditions
- VaricellaMumpsRubellaMeasles
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 944
- Registration Number
- NCT00127023
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
- Conditions
- Heart Failure, Congestive and Microalbuminuria
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1220
- Registration Number
- NCT00123903
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140
- Conditions
- HIV Infection
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00123890
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: Cervarix™Biological: Havrix™-based investigational formulation
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18729
- Registration Number
- NCT00122681
- Locations
- 🇬🇧
GSK Investigational Site, Waterloo, Liverpool, United Kingdom
Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
- Conditions
- Osteoarthritis, Knee
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1340
- Registration Number
- NCT00120900
- Locations
- 🇸🇪
GSK Investigational Site, Helsingborg, Sweden
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults
- Conditions
- Infections, Papillomavirus
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 776
- Registration Number
- NCT00120848
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
- Conditions
- Hepatitis A
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5000
- Registration Number
- NCT00119743
- Locations
- 🇸🇰
GSK Investigational Site, Zlate Moravce, Slovakia
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
- Conditions
- Solid Tumor Cancer
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00119171
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States